Silence Therapeutics (NASDAQ:SLN – Get Free Report) issued its quarterly earnings data on Monday. Silence Therapeutics had a negative return on equity of 105.34% and a negative net margin of 8,943.86%. Silence Therapeutics Trading Up 29.1%Silence Therapeutics stock opened at $15.43 on Tuesday. More Silence Therapeutics NewsHere are the key news stories impacting Silence Therapeutics this week:Positive Sentiment: Positive Phase 2 SANRECO results: Silence reported that divesiran met both the primary and secondary endpoints in a 48-patient Phase 2 trial for phlebotomy-dependent polycythemia vera. Further ReadingReceive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.